2023-509776-41-00招募中1 期
Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).
Instituto Oncologico Dr. Rosell S.L.4 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2024年7月23日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 48
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
A person designed by the Sponsor
Scientific
Instituto Oncologico Dr. Rosell S.L.
研究点 (4)
Loading locations...
相似试验
招募中
2 期
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCNCT07269782Shanghai Henlius Biotech60
尚未招募
2 期
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerNCT07283198Jiangsu Alphamab Biopharmaceuticals Co., Ltd160
尚未招募
1 期
Bladder Perfusion of Plasma-Activated Saline for Bladder CancerNCT07272603Qilu Hospital of Shandong University5
尚未招募
1 期
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsNCT07279428Sichuan Baili Pharmaceutical Co., Ltd.33
招募中
1 期
A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC2024-511956-42-00AstraZeneca AB44